Lipidomic Evaluation of Feline Neurologic Disease after AAV Gene Therapy

Keyphrases

• Neurological Diseases 100%
• Feline 100%
• Lipidomics 100%
• Sphingolipids 100%
• Adeno-associated Virus Gene Therapy 100%
• GM1 Gangliosidosis 66%
• Targeted Lipidomics 66%
• Older Adults 33%
• Disease Progression 33%
• Cerebrospinal Fluid 33%
• Clinical Trials 33%
• Effective Treatment 33%
• Adenovirus 33%
• Coefficient of Determination 33%
• Fold Increase 33%
• Ceramide 33%
• Disease Mechanisms 33%
• Lipid Species 33%
• Pathogenic Mechanism 33%
• Lysosomal Disease 33%
• 5-year-old 33%
• Clinical Signs 33%
• Glycolipids 33%
• α-galactosylceramide (α-GalCer) 33%
• GM1 Ganglioside 33%
• Normal Adults 33%
• Cerebrospinal Fluid Samples 33%
• Lipid Analysis 33%
• Lipid Storage 33%
• Sphingomyelin 33%
• Lipid Metabolites 33%
• Sulfatide 33%
• Marker of Disease Progression 33%
• Humane Endpoints 33%
• Hexosylceramide 33%
• Ganglioside GM3 33%
• Storage Products 33%
• Detergent Additive 33%
• Ganglioside Synthesis 33%
• Adult Control 33%

Biochemistry, Genetics and Molecular Biology

• Gene Therapy 100%
• Lipidomics 100%
• Adeno Associated Virus 100%
• Virus Gene 100%
• GM1 100%
• Cat 100%
• Sphingolipid 60%
• Lipid 40%
• Metabolite 40%
• GM1 Gangliosidosis 40%
• Ganglioside 40%
• Anabolism 20%
• Clinical Trial 20%
• Lifespan 20%
• Sulfatide 20%
• Lactosylceramide 20%
• Lipid Storage Disorder 20%
• GM3 20%
• Ceramide 20%
• Glycolipid 20%
• Sphingomyelin 20%